核磁共振波谱作为提高前列腺癌早期诊断和危险度分级的新方法（英文）

发布时间：2018-04-22 01:20

本文选题：前列腺癌 + 代谢组学　；参考：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2017年11期

【摘要】：前列腺癌(PCA)是全球第二个最常见的男性癌症,同时也是男性癌症死亡的第五大原因。早期发现和危险度分级是提高前列腺癌患者生存率最有效的方法。目前前列腺癌的生物标志物缺乏足够的敏感性和特异性,而代谢产物作为生物标志物可以作为一种新的提高早期诊断的工具。我们检索了154篇出版物,其中27篇和38篇是分别关于尿液和血清代谢组学分析的原研论文,提示了核磁共振波谱分析是一种很有前景的检测方法,可用于测量复杂的样本中代谢物的浓度,具有良好的重现性、高灵敏度和样本处理的便捷性。特别是基于核磁共振的代谢组学检测尿液已成为检测前列腺癌的早期潜在的危险度分级和监测治疗效果的有效的方法。
[Abstract]:Prostate cancer (PCA) is the second most common cancer in men and the fifth leading cause of cancer deaths in men. Early detection and risk grading are the most effective methods to improve the survival rate of prostate cancer patients. At present, the biomarkers of prostate cancer lack sufficient sensitivity and specificity, and metabolites as biomarkers can be used as a new tool to improve early diagnosis. We searched 154 publications, of which 27 and 38 were original papers on urine and serum metabonomics analysis, respectively, suggesting that nuclear magnetic resonance spectroscopy is a promising method for detection. It can be used to measure the concentration of metabolites in complex samples. It has good reproducibility, high sensitivity and convenient sample processing. In particular, metabonomics based on MRI has become an effective method for early detection of prostate cancer potential risk classification and monitoring of therapeutic efficacy.
【作者单位】： Department
【基金】：Project supported by the Joint Research Project(No.PW2016D-13)of Pudong New Area Health and Family Planning Committee,Shanghai,China
【分类号】：R445.2;R737.25

【相似文献】